GlobeNewswire by notified

Förslag till ny styrelseledamot i Aino Health AB

Dela

Roland Norberg föreslås nyväljas till styrelseledamot i Aino Health AB vid bolagets årsstämma på måndagen den 23 maj. Styrelsen kommer därmed att bestå av sex ledamöter.

Roland Norberg
Roland har under 50 års tid drivit bolag både i och utanför Sverige. SMRI, Strategic Market Research Institute, är moderbolag för en mindre privatägd koncern med dotterföretagen SveMa Group, SveMa Svenska Marknadsundersökningar, TellUsNow, SveMa Research Kft, NorMa Nordiska AS samt CDC Fastigheter. Norberg & Partners TGI AB, NPSI AB och Aktiegirot Sverige AB är partnerägt av Roland Norberg.

Roland har en tydlig filantropiskt ådra, vilket har genomsyrat hela hans karriär. Tillsammans med sin bror tog de in över 100 miljoner till Svenska Ishockeyförbundets ungdomssatsning, via Sweden Hockey Pool. Roland Norberg är grundare och styrelseordförande i Norberg & Partner Sustainable Group AB.

Idag är Roland även styrelseordförande i Finansgirot Sverige AB och SveMa Group AB, samt styrelseledamot i SMRI, Strategic Market Research Institute AB, NPSI AB, TGI Management AB, Adeltrad AB, LINK & NEMO AB, AbiCure Sweden AB, Norberg & Partner Capital Invest AB, Norberg & Partner Property Invest AB och VIDANI Holding AB. 


För mer information, vänligen kontakta:
Jyrki Eklund, VD Aino Health
Telefon: +358 40 042 4221
jyrki.eklund@ainohealth.com

Certified Adviser
Erik Penser Bank
+46 8 463 83 00
certifiedadviser@penser.se

Om Aino Health (publ)
Aino Health är den ledande leverantören av Software as a Service-lösningar inom Human Capital Productivity och Employee Sustainability. Företagets kompletta system med SaaS-plattformar och tjänster minskar sjukfrånvaro, sänker relaterade kostnader och förbättrar affärsresultaten genom ökad produktivitet och medarbetarengagemang genom att göra hälsa, välbefinnande och säkerhet till en integrerad del av det dagliga arbetet. För mer information besök ainohealth.com.


För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Bavarian Nordic modtager vaccineordre fra europæisk land efter bekræftede tilfælde af abekopper19.5.2022 11:46:42 CEST | pressemeddelelse

KØBENHAVN, Danmark, 19. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt med et unavngivet europæisk land vedrørende levering af koppevaccinen IMVANEX® i forbindelse med nye tilfælde af abekopper, der er identificeret i løbet af maj 2022. Det første europæiske tilfælde blev bekræftet den 7. maj 2022 hos en person, der vendte hjem fra en rejse til Nigeria, hvor abekopper er naturligt forekommende. Efterfølgende er der bekræftet mere end 20 tilfælde i England, Portugal og Spanien, og flere formodede tilfælde er ved at blive undersøgt. De fleste infektioner lader til at være sket lokalt i de tre lande. I USA er der bekræftet et enkelt tilfælde hos en rejsende fra Canada, hvor der endnu ikke foreligger bekræftede tilfælde, men adskillige formodede tilfælde er ved at blive undersøgt. Bavarian Nordics koppevaccine er godkendt i USA under navnet JYNNEOS® og i Canada under navnet IMVAMUNE®. I begge lande er godkendelsen udvidet til at omfatte abek

Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases19.5.2022 11:46:42 CEST | Press release

COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022. The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation. Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe a

XPENG Oslo Experience Store Now Open With XPENG G3i and XPENG P5 Available for Local Test Drives19.5.2022 11:00:00 CEST | Press release

XPENG opens its first Brand Experience Store in the Bjørvika area of downtown Oslo on May 19, 2022.The launch of the fully electric XPENG P5 and XPENG G3i makes Norway the first European country to boast the full range of XPENG EVs. Local test drives are now available to customers.XPENG, in June this year, will be participating in the 35th International Electric Vehicle Symposium (EVS35) 2022, the world’s largest international EV event live from Oslo. OSLO, Norway, May 19, 2022 (GLOBE NEWSWIRE) -- XPENG, a leading electric vehicle manufacturer, is taking the next step in its European expansion by opening its first Norwegian Brand Experience Store in the Bjørvika area of Oslo on May 19. This coincides with the official launch of the brand's two latest models, XPENG G3i and XPENG P5. Establishing a Local Presence XPENG is one of the early adopters of a disruptive retail model in the European market, combining direct, in-store sales with wider agency collaboration. In the Oslo Brand Exper

IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release

Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed

Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release

Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral